Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › ACHV

Achieve Life Sciences

ACHV Lead: NDA Submitted ★ Read the deep dive → 2 Biotech Distilled articles ↓ 22 filings & releases ↓ Cash $48.0M (Jun 30, 2026) ↓ 2 verdicts ↓
Small Molecule

Market cap $692M 102.9M shares (10-Q, Aug 11, 2026) × $6.72 close Nov 6, 2026

Most recent annual filing: 2026-03-24

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. Cytisinicline smoking cessation NDA filing4Q 2026Cytisinicline smoking cessation NDA filing, 4Q 2026, major
  2. Cytisinicline smoking cessation corporate update4Q 2026/1Q 2027Cytisinicline smoking cessation corporate update, 4Q 2026/1Q 2027, material
  3. Cytisinicline smoking cessation FDA approval1H 2027Cytisinicline smoking cessation FDA approval, 1H 2027, thesis-defining
  4. Cytisinicline vaping cessation Ph3 start~Oct 2027Cytisinicline vaping cessation Ph3 start, ~Oct 2027, routine
  5. Cytisinicline vaping cessation corporate update~Oct 2027Cytisinicline vaping cessation corporate update, ~Oct 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (2 active programs)

Capital (as filed)

Cash
$48.0M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$139M Jun 30, 2026
Operating cash flow
−$10.8M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$187M cash per the deep dive of Aug 11, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (2)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on Achieve Life Sciences, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-08-12 Watch Achieve Life Sciences (ACHV) — Scientific Deep Dive for Cytisinicline and Pipeline Products Good science and a fixable manufacturing CRL, but uninvestable until the Sopharma arbitration and NCE exclusivity question resolve, given no composition-of-matter patent on a public-domain alkaloid.
  2. 2026-08-15 Watch UPDATE: Achieve Life Sciences (ACHV) - The $150M Insurance Policy The $150M ATM bridges the structural dilution gap and de-links launch spending from the approval-triggered warrant clock, but the Sopharma arbitration and NCE exclusivity question remain unresolved, keeping the stock uninvestable.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (22)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 11, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

17 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)